Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2015

Open Access 01-12-2015 | Research article

The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease

Authors: Hadi Emamat, Forough Foroughi, Hassan Eini–Zinab, Mohsen Taghizadeh, Marjan Rismanchi, Azita Hekmatdoost

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2015

Login to get access

Abstract

Background

The aim of this study was to evaluate the effects of onion powder consumption on treatment of Non-alcoholic Fatty Liver Disease (NAFLD) in an experimental model of disease.

Methods

Sprague–Dawley rats were fed high-fat (HF) diet for seven weeks to induce the NAFLD. Then, they were treated by either the same diet (HF), or high-fat diet plus 7 % onion powder (HF + onion), or chow diet (control), or chow diet plus 7 % onion powder (control + onion)ad libitum for four weeks. Serum levels of fasting glucose, triglyceride, cholesterol, liver enzymes, insulin, and hepatic tumor necrosis factor-alpha (TNF-α) gene expression were determined. Hepatic histology was examined by Hematoxylin and Eosin stain.

Results

Dietary food intakes and weigh gain were significantly more in animals fed control + onion diet in comparison to the other groups. Animals fed control or control + onion diet had significantly lower plasma levels of hepatic enzymes, lipid profile, glycemic indices, and hepatic TNF-α gene expression as compared with HF diet fed groups; however, there was no significant difference in the histopathologic features of NAFLD among different groups.

Conclusion

Our results indicate that onion consumption can be effective in NAFLD management when it is combined with a healthy diet.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005–23.CrossRefPubMed Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005–23.CrossRefPubMed
2.
go back to reference Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig. 2013;4(6):517–24.CrossRefPubMedPubMedCentral Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig. 2013;4(6):517–24.CrossRefPubMedPubMedCentral
3.
go back to reference Eslamparast T, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535–42.CrossRefPubMed Eslamparast T, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535–42.CrossRefPubMed
4.
go back to reference Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796–803.CrossRefPubMed Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114(5):796–803.CrossRefPubMed
6.
go back to reference Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34(2):143–8.CrossRefPubMed Askari F, Rashidkhani B, Hekmatdoost A. Cinnamon may have therapeutic benefits on lipid profile, liver enzymes, insulin resistance, and high-sensitivity C-reactive protein in nonalcoholic fatty liver disease patients. Nutr Res. 2014;34(2):143–8.CrossRefPubMed
7.
go back to reference Faghihzadeh F, et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–43.CrossRefPubMed Faghihzadeh F, et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34(10):837–43.CrossRefPubMed
8.
9.
go back to reference Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future. World J Hepatol. 2015;7(25):2597–602.CrossRefPubMedPubMedCentral Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: present and the future. World J Hepatol. 2015;7(25):2597–602.CrossRefPubMedPubMedCentral
11.
go back to reference Liao YR, Lin JY. Quercetin intraperitoneal administration ameliorates lipopolysaccharide-induced systemic inflammation in mice. Life Sci. 2015;137:89–97.CrossRefPubMed Liao YR, Lin JY. Quercetin intraperitoneal administration ameliorates lipopolysaccharide-induced systemic inflammation in mice. Life Sci. 2015;137:89–97.CrossRefPubMed
12.
go back to reference Alam MM, Meerza D, Naseem I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci. 2014;109(1):8–14.CrossRefPubMed Alam MM, Meerza D, Naseem I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci. 2014;109(1):8–14.CrossRefPubMed
13.
go back to reference Slimestad R, Fossen T, Vagen IM. Onions: a source of unique dietary flavonoids. J Agric Food Chem. 2007;55(25):10067–80.CrossRefPubMed Slimestad R, Fossen T, Vagen IM. Onions: a source of unique dietary flavonoids. J Agric Food Chem. 2007;55(25):10067–80.CrossRefPubMed
14.
go back to reference Adesso S, et al. Anti-inflammatory and anti-oxidant activity of polyphenolic extracts from Lactuca sativa (var. Maravilla de Verano) under different farming methods. J Sci Food Agric. 2016. doi: 10.1002/jsfa.7622. [Epub ahead of print]. Adesso S, et al. Anti-inflammatory and anti-oxidant activity of polyphenolic extracts from Lactuca sativa (var. Maravilla de Verano) under different farming methods. J Sci Food Agric. 2016. doi: 10.​1002/​jsfa.​7622. [Epub ahead of print].
15.
go back to reference Emamat H, et al. An accessible and pragmatic experimental model of nonalcoholic fatty liver disease. Middle East J Dig Dis. 2016;8(2):1–7.CrossRef Emamat H, et al. An accessible and pragmatic experimental model of nonalcoholic fatty liver disease. Middle East J Dig Dis. 2016;8(2):1–7.CrossRef
16.
go back to reference Hamauzu Y, et al. Physicochemical characteristics of rapidly dried onion powder and its anti-atherogenic effect on rats fed high-fat diet. Food Chem. 2011;129(3):810–5.CrossRefPubMed Hamauzu Y, et al. Physicochemical characteristics of rapidly dried onion powder and its anti-atherogenic effect on rats fed high-fat diet. Food Chem. 2011;129(3):810–5.CrossRefPubMed
17.
go back to reference Ackerman Z, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005;45(5):1012–8.CrossRefPubMed Ackerman Z, et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005;45(5):1012–8.CrossRefPubMed
18.
go back to reference Dhibi M, et al. The intake of high fat diet with different trans fatty acid levels differentially induces oxidative stress and non alcoholic fatty liver disease (NAFLD) in rats. Nutr Metab (Lond). 2011;8(1):65.CrossRef Dhibi M, et al. The intake of high fat diet with different trans fatty acid levels differentially induces oxidative stress and non alcoholic fatty liver disease (NAFLD) in rats. Nutr Metab (Lond). 2011;8(1):65.CrossRef
19.
go back to reference Safwat GM, et al. Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect? Nutrition. 2009;25(11–12):1157–68.CrossRefPubMed Safwat GM, et al. Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect? Nutrition. 2009;25(11–12):1157–68.CrossRefPubMed
20.
go back to reference Xu ZJ, et al. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci. 2010;55(4):931–40.CrossRefPubMed Xu ZJ, et al. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci. 2010;55(4):931–40.CrossRefPubMed
21.
go back to reference Brunt EM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467–74.CrossRefPubMed Brunt EM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467–74.CrossRefPubMed
22.
go back to reference Jaiswal N, Rizvi SI. Onion extract (Allium cepa L.), quercetin and catechin up-regulate paraoxonase 1 activity with concomitant protection against low-density lipoprotein oxidation in male Wistar rats subjected to oxidative stress. J Sci Food Agric. 2014;94(13):2752–7.CrossRefPubMed Jaiswal N, Rizvi SI. Onion extract (Allium cepa L.), quercetin and catechin up-regulate paraoxonase 1 activity with concomitant protection against low-density lipoprotein oxidation in male Wistar rats subjected to oxidative stress. J Sci Food Agric. 2014;94(13):2752–7.CrossRefPubMed
23.
go back to reference Wang BS, et al. Anti-inflammatory effects of an aqueous extract of Welsh onion green leaves in mice. Food Chem. 2013;138(2–3):751–6.CrossRefPubMed Wang BS, et al. Anti-inflammatory effects of an aqueous extract of Welsh onion green leaves in mice. Food Chem. 2013;138(2–3):751–6.CrossRefPubMed
24.
go back to reference Lee B, Jung JH, Kim HS. Assessment of red onion on antioxidant activity in rat. Food Chem Toxicol. 2012;50(11):3912–9.CrossRefPubMed Lee B, Jung JH, Kim HS. Assessment of red onion on antioxidant activity in rat. Food Chem Toxicol. 2012;50(11):3912–9.CrossRefPubMed
25.
go back to reference Jung JY, et al. Onion peel extracts ameliorate hyperglycemia and insulin resistance in high fat diet/streptozotocin-induced diabetic rats. Nutr Metab (Lond). 2011;8(1):18.CrossRef Jung JY, et al. Onion peel extracts ameliorate hyperglycemia and insulin resistance in high fat diet/streptozotocin-induced diabetic rats. Nutr Metab (Lond). 2011;8(1):18.CrossRef
26.
27.
go back to reference An BK, et al. Effects of onion extracts on growth performance, carcass characteristics and blood profiles of white mini broilers. Asian-Australas J Anim Sci. 2015;28(2):247–51.CrossRefPubMedPubMedCentral An BK, et al. Effects of onion extracts on growth performance, carcass characteristics and blood profiles of white mini broilers. Asian-Australas J Anim Sci. 2015;28(2):247–51.CrossRefPubMedPubMedCentral
28.
go back to reference Jatzlau A, et al. Nature helps: food addition of micronized coconut and onion reduced worm load in horses and sheep and increased body weight in sheep. Parasitol Res. 2014;113(1):305–10.CrossRefPubMed Jatzlau A, et al. Nature helps: food addition of micronized coconut and onion reduced worm load in horses and sheep and increased body weight in sheep. Parasitol Res. 2014;113(1):305–10.CrossRefPubMed
29.
go back to reference Kook S, Kim GH, Choi K. The antidiabetic effect of onion and garlic in experimental diabetic rats: meta-analysis. J Med Food. 2009;12(3):552–60.CrossRefPubMed Kook S, Kim GH, Choi K. The antidiabetic effect of onion and garlic in experimental diabetic rats: meta-analysis. J Med Food. 2009;12(3):552–60.CrossRefPubMed
Metadata
Title
The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease
Authors
Hadi Emamat
Forough Foroughi
Hassan Eini–Zinab
Mohsen Taghizadeh
Marjan Rismanchi
Azita Hekmatdoost
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2015
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-016-0248-4

Other articles of this Issue 1/2015

Journal of Diabetes & Metabolic Disorders 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.